Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.07.2022 | Clinical study

Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Safety findings for COVID-19 mRNA vaccine first booster doses among persons with presumed immunocompromise status are similar to those among non-immunocompromised persons. …
Literatur
Zurück zum Zitat Hause AM, et al. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ?12 Years with Presumed Immunocompromise Status ? United States, January 12, 2022?March 28, 2022 Morbidity and Mortality Weekly Report : 20 Jul 2022. Available from: URL: https://doi.org/10.15585/mmwr.mm7128a3 Hause AM, et al. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ?12 Years with Presumed Immunocompromise Status ? United States, January 12, 2022?March 28, 2022 Morbidity and Mortality Weekly Report : 20 Jul 2022. Available from: URL: https://​doi.​org/​10.​15585/​mmwr.​mm7128a3
Metadaten
Titel
Safety of COVID-19 mRNA vaccine first booster doses among immunocompromised persons
Publikationsdatum
01.07.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-19882-1

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Imatinib

Case report

Antineoplastics

Case report

Pembrolizumab

Case report

Multiple drugs

Case report

Tozinameran